{"title":"间变性大细胞淋巴瘤及其形态变异。","authors":"M E Kadin","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Clinicopathological studies have identified CD30+ ALCL as a clinicopathological entity with heterogeneous morphology and a frequent translocation involving t(2;5), with a better prognosis than most other T cell neoplasms and a different natural history and prognosis than Hodgkin's disease. Because of the different natural history and prognosis of CD30+ ALCL, it is important to recognize this entity and its morphological variants. Further studies are indicated to determine whether specific clinical management(s) and therapies are necessary for variants of ALCL such as HD like ALCL and the small cell predominant type.</p>","PeriodicalId":77062,"journal":{"name":"Cancer surveys","volume":"30 ","pages":"77-86"},"PeriodicalIF":0.0000,"publicationDate":"1997-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anaplastic large cell lymphoma and its morphological variants.\",\"authors\":\"M E Kadin\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Clinicopathological studies have identified CD30+ ALCL as a clinicopathological entity with heterogeneous morphology and a frequent translocation involving t(2;5), with a better prognosis than most other T cell neoplasms and a different natural history and prognosis than Hodgkin's disease. Because of the different natural history and prognosis of CD30+ ALCL, it is important to recognize this entity and its morphological variants. Further studies are indicated to determine whether specific clinical management(s) and therapies are necessary for variants of ALCL such as HD like ALCL and the small cell predominant type.</p>\",\"PeriodicalId\":77062,\"journal\":{\"name\":\"Cancer surveys\",\"volume\":\"30 \",\"pages\":\"77-86\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1997-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer surveys\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer surveys","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Anaplastic large cell lymphoma and its morphological variants.
Clinicopathological studies have identified CD30+ ALCL as a clinicopathological entity with heterogeneous morphology and a frequent translocation involving t(2;5), with a better prognosis than most other T cell neoplasms and a different natural history and prognosis than Hodgkin's disease. Because of the different natural history and prognosis of CD30+ ALCL, it is important to recognize this entity and its morphological variants. Further studies are indicated to determine whether specific clinical management(s) and therapies are necessary for variants of ALCL such as HD like ALCL and the small cell predominant type.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
